Most Read Articles
15 Mar 2019
Roche recently announced their targeted therapy combination pertuzumab (Perjeta®)-trastuzumab (Herceptin®) plus conventional chemotherapy for treatment of early breast cancer in those with a subtype known as HER2-positive. The combination was previously used in the metastatic breast cancer setting, where cancer had already spread. There, it was able to prolong cancer sufferers’ lives significantly. Because of its effectiveness, the two-drug combo is new available for treatment of early HER2-positive breast cancer to further reduce the risk of metastasis or cancer recurrence. HER2-positive breast cancers usually spread faster and affect younger women and make up about one quarter of all newly diagnosed breast cancers. 

Clinical genetic testing in HBOC syndrome

Dr Joslyn Ngu
04 Dec 2017

Hereditary breast and ovarian cancer (HBOC) syndrome, which is primarily caused by BRCA1 and BRCA2 mutations, make up 8 to 10 percent of all breast cancers, says a senior consultant.

The inheritance pattern is autosomal dominant and rarely de novo, said Associate Professor Joanne Ngeow Yuen Yie, head of the Cancer Genetics Service, National Cancer Centre Singapore and senior consultant in Division of Medical Oncology at the same centre.

In those with HBOC syndrome, the risk of developing breast cancer by age 70 is 56 to 87 percent, and the risk of developing ovarian cancer is 27 to 44 percent by the age of 75, she said. Besides elevated risk of breast and ovarian cancer, those with HBOC syndrome is also at a higher risk of developing prostate cancer, melanoma and pancreatic cancer.

Genetic counselling for HBOC syndrome should be provided to those with a personal history of or close family member with, for instance: ovarian, fallopian tube or primary peritoneal cancer; breast cancer diagnosed before the age of 50; and men with breast cancer, explained Ngeow.

Currently, there are more than 400 hereditary cancer syndromes identified and the number will increase, she said. Pre- and post-genetic test counselling are important so there is shared decision-making for gene-directed management.

Panel testing will be the way forward. As it is new, there will be pitfalls and clinicians need to be aware of them, Ngeow concluded.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
15 Mar 2019
Roche recently announced their targeted therapy combination pertuzumab (Perjeta®)-trastuzumab (Herceptin®) plus conventional chemotherapy for treatment of early breast cancer in those with a subtype known as HER2-positive. The combination was previously used in the metastatic breast cancer setting, where cancer had already spread. There, it was able to prolong cancer sufferers’ lives significantly. Because of its effectiveness, the two-drug combo is new available for treatment of early HER2-positive breast cancer to further reduce the risk of metastasis or cancer recurrence. HER2-positive breast cancers usually spread faster and affect younger women and make up about one quarter of all newly diagnosed breast cancers.